Profile data is unavailable for this security.
About the company
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
- Revenue in EUR (TTM)463.85m
- Net income in EUR94.75m
- Incorporated--
- Employees1.75k
- LocationFaes Farma SAAvda. Autonomia 10LEIOA 48940SpainESP
- Phone+34 944818300
- Fax+34 944818301
- Websitehttps://faesfarma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formycon AG | 77.70m | 75.80m | 771.61m | 238.00 | 9.30 | 1.40 | 9.93 | 9.93 | 4.70 | 4.70 | 4.84 | 31.32 | 0.0891 | 104.80 | 3.56 | 326,453.80 | 8.69 | 5.87 | 9.33 | 6.33 | 30.00 | 28.54 | 97.55 | 39.76 | 0.9621 | -0.0189 | 0.0176 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Swedencare AB (publ) | 207.70m | 6.15m | 796.33m | 552.00 | 129.43 | 1.19 | 24.14 | 3.83 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| Abivax SA | 0.00 | -147.74m | 828.14m | 40.00 | -- | 4.22 | -- | -- | -3.35 | -3.35 | 0.00 | 3.12 | 0.00 | -- | -- | 0.00 | -73.79 | -65.49 | -96.88 | -94.75 | -- | -- | -- | -- | -- | -8.05 | 0.2206 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Eckert & Ziegler SE | 255.78m | 34.32m | 976.87m | 1.07k | 28.02 | 4.09 | 20.08 | 3.82 | 1.65 | 1.44 | 12.27 | 11.29 | 0.5834 | 3.08 | 4.72 | 237,931.20 | 7.98 | 8.50 | 9.75 | 10.23 | 48.42 | 48.61 | 13.68 | 14.00 | 2.24 | 21.89 | 0.1919 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
| BioGaia AB | 111.91m | 31.95m | 1.06bn | 211.00 | 34.57 | 5.92 | 31.24 | 9.51 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Polypeptide Group AG | 324.72m | -51.42m | 1.10bn | 1.20k | -- | 2.87 | -- | 3.39 | -1.54 | -1.54 | 9.72 | 11.46 | 0.5137 | 2.31 | 5.08 | 267,765.80 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| AddLife AB | 843.14m | 6.80m | 1.15bn | 2.29k | 174.61 | 2.67 | 13.10 | 1.36 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| FAES Farma SA | 463.85m | 94.75m | 1.17bn | 1.75k | 12.05 | -- | 10.22 | 2.52 | 0.3066 | 0.3066 | 1.50 | -- | -- | -- | -- | 265,361.00 | -- | 13.07 | -- | 15.20 | 66.19 | 64.10 | 20.36 | 19.79 | -- | -- | -- | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 185.98m | 78.64m | 1.20bn | 1.12k | 15.21 | 1.20 | 12.70 | 6.43 | 4.00 | 4.00 | 9.46 | 50.85 | 0.1578 | 3.00 | 4.85 | -- | 6.67 | 8.82 | 7.16 | 9.40 | 33.76 | 32.94 | 42.29 | 58.23 | 1.14 | -- | 0.0813 | -- | 86.94 | 56.41 | -8.16 | 62.73 | 141.59 | 31.51 |
| Vetoquinol SA | 529.27m | 55.56m | 1.24bn | 2.48k | 22.28 | 2.35 | 15.37 | 2.35 | 4.70 | 4.70 | 44.73 | 44.53 | 0.7876 | 2.39 | 5.74 | 213,157.90 | 8.27 | 7.09 | 10.44 | 9.40 | 50.31 | 61.27 | 10.50 | 8.84 | 1.86 | -- | 0.0324 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| Cosmo Pharmaceuticals NV | 96.68m | 1.15m | 1.30bn | 325.00 | 1,040.75 | 2.79 | 83.31 | 13.44 | 0.0706 | 0.0706 | 5.94 | 26.34 | 0.1473 | 3.06 | 2.88 | 294,862.20 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Fagron NV | 762.99m | 70.55m | 1.35bn | 3.46k | 19.12 | 2.91 | 12.54 | 1.77 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Biotest AG | 782.60m | 176.90m | 1.38bn | 2.43k | 9.31 | 3.12 | -- | 1.76 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| BioArctic AB | 21.70m | -10.51m | 1.41bn | 90.00 | -- | 19.84 | -- | 65.13 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Genus plc | 790.89m | 39.24m | 1.45bn | 3.48k | 36.97 | 2.15 | 16.00 | 1.83 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
| Bonesupport Holding AB | 56.43m | 22.94m | 1.45bn | 121.00 | 63.49 | 29.81 | 60.91 | 25.74 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
Data as of May 23 2024. Currency figures normalised to Faes Farma SA's reporting currency: Euro EUR
15.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 10.91m | 3.45% |
| Alantra EQMC Asset Management SGIIC SAas of 04 Dec 2023 | 9.53m | 3.02% |
| Norges Bank Investment Managementas of 10 Nov 2022 | 9.28m | 2.93% |
| BlackRock Fund Advisorsas of 09 May 2024 | 4.77m | 1.51% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 4.57m | 1.44% |
| Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 3.45m | 1.09% |
| Argenta Spaarbank NVas of 30 Jun 2023 | 2.14m | 0.68% |
| Santander Asset Management SA SGIICas of 31 Dec 2023 | 2.10m | 0.66% |
| KBC Asset Management NVas of 31 Dec 2023 | 2.08m | 0.66% |
| Praude Asset Management Ltd.as of 28 Feb 2023 | 1.24m | 0.39% |
More ▼
Data from 31 Aug 2023 - 26 Apr 2024Source: FactSet Research Systems Inc.
